Shallcross Steven a, CEO and CFO at Theriva Biologics, Inc. (TOVX), bought 14,000 shares at $0.69 ($10K) on 2023-06-07, disclosed to the SEC on 2023-06-08.
Open-market purchase of $10k TOVX by CEO and CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| TOVX | BUY | 2023-02-03 | $24K | — | Filing → |
| TOVX | BUY | 2023-01-26 | $22K | — | Filing → |
| TOVX | BUY | 2023-01-23 | $19K | — | Filing → |